New antibiotic '100-times more effective at treating TB'
The KKL-35 antibiotic could treat anthrax and tuberculosis by disrupting trans-translation.
A team of scientists led by Penn State University's Kenneth Keiler have discovered a new antibiotic that could be 100-times more effective than current therapies at treating tuberculosis (TB).
Researchers analysed and tested thousands of molecules in order to identify those which effectively disturbed the process of trans-translation in bacteria - one called KKL-35 has shown most promise.
This biological procedure helps ensure that protein synthesis functions properly in these pathogens, so its disruption can prevent the multiplication and spread of bacteria, curbing infection.
Experimenters tested the efficacy of molecules at disturbing trans-translation in Shigella, Bacillus anthracis and Mycobacterium tuberculosis strains. Successful inhibition by KKL-35 suggests it could have clinical applications.
"In our laboratory experiments, we found no mutant strains that were resistant to KKL-35," Keller said. "Resistant mutants probably would evolve eventually, but at least it looks like it will be very difficult."
The antibiotic was up to 100-times more effective at restricting growth of bacteria, but the outcome was only witnessed in a petri dish - a clinical trial in human volunteers may be the next step for determining benefits of the drug.
Related News
-
News Abortion pills can now be sold in retail pharmacies according to the US FDA
In the US, retail pharmacies will be allowed to sell abortion pills for the first time, after latest approval is granted by the FDA. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News Trend Report: The True Cost of API Price Rises
Download our Trend Report to discover what the current landscape of APIs and their pricing means for the pharmaceutical industry in the future. -
News Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance